1800-272-662
Shopping Cart 0
countryflagAU
Login

HLS Therapeutics Inc

Healthcare CA HLS

4.29CAD
0.02(0.47%)

Last update at 2026-03-12T20:00:00Z

Day Range

4.224.34
LowHigh

52 Week Range

3.905.76
LowHigh

Fundamentals

  • Previous Close 4.27
  • Market Cap141.27M
  • Volume4720
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA17.10M
  • Revenue TTM55.85M
  • Revenue Per Share TTM1.76
  • Gross Profit TTM 40.11M
  • Diluted EPS TTM-0.61

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -15.58200M -27.80300M -23.72200M -11.80800M -16.29900M
Minority interest - - - - -
Net income -19.65500M -27.53100M -23.59800M -13.11700M -15.33100M
Selling general administrative 10.20M 8.39M 17.73M 17.40M 18.48M
Selling and marketing expenses 16.73M 19.90M 17.85M 14.66M 12.90M
Gross profit 47.62M 55.45M 56.49M 56.04M 52.48M
Reconciled depreciation 22.72M 31.94M 34.40M 30.26M 33.19M
Ebit -5.49900M -19.05500M -13.44000M -6.24000M -11.25600M
Ebitda 17.22M 12.88M 20.96M 24.02M 21.93M
Depreciation and amortization 22.72M 31.94M 34.40M 30.26M 33.19M
Non operating income net other - - - - -
Operating income -7.68600M -10.34900M -13.44000M -6.24000M -11.25600M
Other operating expenses 64.31M 63.07M 74.96M 66.29M 68.20M
Interest expense 10.08M 8.75M 7.32M 6.96M 6.31M
Tax provision 4.07M -0.27200M -0.12400M 1.31M -0.96800M
Interest income 0.32M 0.35M 0.06M 0.04M 0.32M
Net interest income -9.76400M -8.39800M -7.26000M -6.91200M -5.98500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.07M -0.27200M -0.12400M 1.31M -0.96800M
Total revenue 56.62M 63.07M 61.47M 60.01M 56.11M
Total operating expenses 55.31M 55.45M 69.98M 62.32M 64.57M
Cost of revenue 9.00M 7.62M 4.98M 3.97M 3.62M
Total other income expense net -7.89600M -17.45400M -10.28200M -5.56800M -5.04300M
Discontinued operations - - - - -
Net income from continuing ops -19.65500M -27.53100M -23.59800M -13.11700M -15.33100M
Net income applicable to common shares -19.65500M -27.53100M -23.59800M -13.11700M -15.33100M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 159.90M 209.06M 241.65M 275.90M 303.91M
Intangible assets 122.12M 162.34M 195.02M 229.18M 253.40M
Earning assets - - - - -
Other current assets - 1.92M 3.56M 4.52M 2.17M
Total liab 88.56M 111.36M 116.33M 115.17M 134.66M
Total stockholder equity 71.34M 97.70M 125.32M 160.74M 169.25M
Deferred long term liab - - - - -
Other current liab 0.03M 1.72M 6.01M 5.75M 11.28M
Common stock - 262.13M 265.21M 265.92M 257.41M
Capital stock 260.60M 262.13M 265.21M 265.92M 257.41M
Retained earnings -194.18000M -175.45700M -148.44900M -119.85700M -101.57500M
Other liab - - 1.38M 2.54M -
Good will - - - - -
Other assets - - 1.13M 1.40M 3.21M
Cash 17.46M 21.95M 20.72M 21.18M 20.61M
Cash and equivalents - - 20.72M 21.18M 20.61M
Total current liabilities 22.55M 26.69M 31.19M 27.67M 35.64M
Current deferred revenue - 5.71M - - 5.06M
Net debt 48.11M 65.67M 76.62M 76.39M 86.51M
Short term debt - 5.16M 13.58M 12.61M 10.14M
Short long term debt 4.83M 4.69M 13.06M 12.00M 9.75M
Short long term debt total - 87.62M 97.34M 97.57M 107.12M
Other stockholder equity - 13.87M 13.82M 11.72M 11.39M
Property plant equipment - - 1.13M 1.57M 1.38M
Total current assets 35.40M 44.09M 44.37M 43.75M 45.91M
Long term investments - - - - -
Net tangible assets - - -69.70000M -68.44500M -84.15500M
Short term investments - - - - -
Net receivables 6.72M 10.69M 11.19M 11.51M 12.50M
Long term debt 60.74M 82.05M 83.28M 84.13M 96.20M
Inventory 9.06M 9.53M 8.90M 8.93M 10.63M
Accounts payable 8.71M 14.11M 11.59M 9.32M 14.22M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -2.83800M -5.26000M 2.96M 2.02M
Additional paid in capital - - - - -
Common stock total equity - - - - 257.41M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.53M 0.62M 0.67M 0.71M 2.03M
Deferred long term asset charges - - - - -
Non current assets total 124.50M 164.97M 197.28M 232.15M 258.00M
Capital lease obligations 0.88M 0.88M 1.01M 1.43M 1.17M
Long term debt total - - 83.76M 84.96M 96.98M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 11.73M -0.18900M -10.14800M -4.51000M -44.67700M
Change to liabilities - - 3.24M -3.64600M -0.07000M
Total cashflows from investing activities 11.73M -0.18900M -10.14800M -4.51000M -44.67700M
Net borrowings -21.57300M -9.46300M -0.44100M -11.13700M 13.34M
Total cash from financing activities -23.36400M -14.63900M -6.85600M -11.39800M 9.56M
Change to operating activities - - -0.70700M -1.73900M -1.23600M
Net income -19.65500M -27.53100M -23.59800M -13.11700M -15.33100M
Change in cash -4.49600M 1.23M -0.45600M 0.57M -26.46600M
Begin period cash flow 21.95M 20.72M 21.18M 20.61M 47.08M
End period cash flow 17.46M 21.95M 20.72M 21.18M 20.61M
Total cash from operating activities 8.00M 15.79M 16.94M 16.43M 9.34M
Issuance of capital stock - - - - 0.00000M
Depreciation 22.72M 31.94M 34.40M 30.26M 33.19M
Other cashflows from investing activities 13.25M -0.14800M -10.00000M -3.82000M -12.05000M
Dividends paid 0.00000M -2.39800M 4.96M 5.12M 4.75M
Change to inventory -0.18900M -0.66100M -0.62200M 1.77M -8.07700M
Change to account receivables 2.37M 0.63M -0.07100M 1.04M 1.52M
Sale purchase of stock -0.60000M -1.55200M -0.99800M -0.04700M 1.64M
Other cashflows from financing activities -1.19100M -1.22600M 9.54M 4.91M 20.98M
Change to netincome - - 4.59M 2.30M -0.84600M
Capital expenditures 0.01M 0.19M 10.15M 4.51M 44.68M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.14M 5.04M 1.55M -3.02100M -7.66500M
Stock based compensation 1.62M -0.53800M 2.92M 2.35M 2.53M
Other non cash items -1.62900M 7.58M 1.53M -1.18700M -0.89400M
Free cash flow 7.99M 15.60M 6.79M 11.92M -35.33300M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HLS
HLS Therapeutics Inc		 0.02 0.47% 4.29 - 185.19 2.53 1.67 2.62 8.90
BHC
Bausch Health Companies Inc		 -0.02 0.29% 6.87 5.94 1.34 0.29 18.74 2.18 6.64
CURA
Curaleaf Holdings Inc.		 - -% 3.15 - 138.89 1.90 2.05 1.88 11.75
CRON
Cronos Group Inc		 0.06 1.77% 3.45 23.40 32.26 10.16 0.92 1.27 -1.9458
TLRY
Tilray Inc		 0.11 1.16% 9.62 - 1000.00 1.34 0.56 1.09 -2.299

Reports Covered

Stock Research & News

View All

Profile

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company's lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

HLS Therapeutics Inc

10 Carlson Court, Etobicoke, ON, Canada, M9W 6L2

Key Executives

Name Title Year Born
Mr. Gregory David Gubitz B.A., L.L.B., LL.B Co-Founder & Chairman 1957
Mr. Gilbert Godin Co-Founder, CEO & Director 1959
Mr. Tim Hendrickson M.B.A. Chief Financial Officer 1972
Mr. Sanjiv Sharma Chief Commercial Officer 1956
Mr. Ryan C. Lennox B.A., J.D. Sr. VP of Legal, HR & Compliance and Corp. Sec. 1981
David Spence Corp. Controller 1968
Mr. Craig Stuart Millian M.B.A. CEO & Director 1968
Mr. John Hanna CPA, CGA, M.B.A. CFO & Non-Independent Director 1965
Dr. Jason A. Gross Pharm.D. Vice President of Scientific Affairs 1965
Mr. Ryan C. Lennox B.A., J.D. Senior VP of Legal, HR & Compliance and Corporate Secretary 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.